FDA
-
-
-
-
-
-
-
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
-
-
-
-
-
-
-
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
EyePoint Announces Participation at Upcoming Investor Conferences
-
-
-
-
-
-
-
EyePoint initiates Phase 3 trials for DURAVYU in diabetic macular edema
-
-
-
-
-
-
-
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
-
327,061 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

